FibroGen (NASDAQ:FGEN) Upgraded by HC Wainwright to “Strong-Buy” Rating

HC Wainwright upgraded shares of FibroGen (NASDAQ:FGEN) to a strong-buy rating in a research note released on Tuesday,Zacks.com reports. HC Wainwright also issued estimates for FibroGen’s Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.74) EPS, FY2025 earnings at ($0.53) EPS, FY2026 earnings at ($0.56) EPS, FY2027 earnings at ($0.44) EPS and FY2028 earnings at ($0.44) EPS.

Other equities analysts also recently issued reports about the company. StockNews.com started coverage on FibroGen in a report on Monday. They issued a “hold” rating on the stock. William Blair reaffirmed a “market perform” rating on shares of FibroGen in a research report on Wednesday, November 13th.

FibroGen Stock Up 3.3 %

Shares of FGEN opened at $0.35 on Tuesday. The company has a 50-day simple moving average of $0.35 and a 200-day simple moving average of $0.57. FibroGen has a 52-week low of $0.18 and a 52-week high of $2.93. The company has a market capitalization of $35.64 million, a PE ratio of -0.29 and a beta of 0.82.

FibroGen (NASDAQ:FGEN) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.21. The firm had revenue of $46.33 million for the quarter, compared to analyst estimates of $34.00 million. During the same period last year, the firm earned ($0.52) EPS. On average, research analysts anticipate that FibroGen will post -0.86 EPS for the current year.

Institutional Trading of FibroGen

Several institutional investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC lifted its stake in FibroGen by 3,906.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 280,161 shares in the last quarter. Point72 DIFC Ltd boosted its holdings in FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 45,990 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of FibroGen during the 2nd quarter valued at about $424,000. Acadian Asset Management LLC raised its position in shares of FibroGen by 34.4% in the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after purchasing an additional 860,854 shares during the period. Finally, Sei Investments Co. lifted its position in FibroGen by 38.4% during the 2nd quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 41,442 shares during the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.